79-year-old male patient with a 2-point improvement in IGA PN-S

Current PN therapy: DUPIXENT 300 mg Q2W

This adult patient was an actual patient (not a clinical trial participant) treated with DUPIXENT for ≥24 weeks. Scoring was designated by the healthcare professional. Because this patient was a real-world patient, other factors may have influenced treatment results, and individual results may vary.

DRAG TO SEE
RESULTS
DRAG TO SEE
RESULTS

SIGNIFICANT NODULE CLEARANCE

DUPIXENT patients achieved significant reduction in nodules vs placebo at Week
24 (secondary endpoint)1-3

PRIME
Proportion (%) of patients with IGA PN-S score of 0 or 1 at Week 241-3,a
  • A nominal difference was observed at Week 4 (9% with DUPIXENT vs 1% with placebo) and at Week 12 (32% with DUPIXENT vs 12% with placebo)3

Definitive conclusions cannot be made for results earlier than 24 weeks in PRIME. Data were not multiplicity controlled.

PRIME2


  • At Week 4, 8% of patients treated with DUPIXENT vs 6% with placebo had nodule clearance. A significantly greater proportion of DUPIXENT patients achieved nodule clearance at Week 12 (26% with DUPIXENT vs 12% with placebo; P=0.019) and Week 24 (45% with DUPIXENT vs 16% with placebo; P<0.001)1-3

Definitive conclusions cannot be made for results at timepoints other than Week 12 and 24 in PRIME2. Data were not multiplicity controlled.

DUPIXENT DEMONSTRATED SIGNIFICANT NODULE CLEARANCE

PRIME

At baseline:

29% of patients
had an IGA PN-S
score
of 4 (over
100 nodules)1,2,a

71% of patients
had an IGA PN-S
score
of 3
(20-100
nodules)1,2

At Week 24:

48% of DUPIXENT
patients

improved to an
IGA PN-S score of
0 or 1 (5 nodules
or fewer)
compared with
18% with
placebo1,2
 

Illustrative representation of nodule clearance based on clinical trial results.
Actual individual results may vary.
 

Click and drag
to see results

Illustrative representation of nodule clearance based on clinical trial results. Actual individual results may vary. 


IGA PN-S ranges from 0 (clear, no nodules) to 1 (almost clear, ≤5 nodules), 2 (mild, 6-19 nodules), 3 (moderate, 20-99 nodules), and 4 (severe, ≥100 nodules).

  • In PRIME2, 38% of patients had 100 or more nodules at baseline, with 45% of all DUPIXENT patients achieving 5 nodules or fewer at Week 24 vs 16% with placebo1,2

bAll study participants had ≥20 nodules upon screening and at Day 1 (inclusion criteria).

DUPIXENT showed consistent efficacy regardless of patients’ atopic
background1,4

POOLED ANALYSIS:
PRIME AND PRIME2

Nodule improvement regardless of patients’ history of atopy1,4

Proportion of patients with IGA PN-S score of 0 or 1 at Week 24

Definitive conclusions cannot be made for these results as the data were not
multiplicity controlled and P values were nominal.

In the PRIME trials, patients were stratified by their history of atopy.

57%
of patients across PRIME and PRIME2 did not have a history of atopy (defined as having a medical history of atopic dermatitis, allergic rhinitis/rhinoconjunctivitis, asthma, or food allergy)1

Explore COMPOSITE
ENDPOINT

Explore composite endpoint

IGA PN-S, Investigator’s Global Assessment PN-Stage; Q2W, once every 2 weeks; SD, standard deviation.